179003-08-8

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-(1-piperazinyl)benzoate is utilized as a building block for the synthesis of various drugs and active pharmaceutical ingredients. Its structural features allow for the creation of compounds with a range of biological activities.
Used in Anticancer Research:
Methyl 3-(1-piperazinyl)benzoate is used as a potential anticancer agent in preclinical studies, where it has shown properties that could be beneficial in combating cancer.
Used in Anticonvulsant Development:
Methyl 3-(1-piperazinyl)benzoate is also used as a starting material in the development of anticonvulsant drugs, given its reported anticonvulsant properties in preclinical studies.
Used in Antihyperglycemic Drug Synthesis:
Methyl 3-(1-piperazinyl)benzoate is used in the synthesis of antihyperglycemic agents, indicating its potential role in managing blood sugar levels.
Used in Central Nervous System Depressant and Anxiolytic Drug Research:
Methyl 3-(1-piperazinyl)benzoate has been investigated for its potential as a central nervous system depressant and anxiolytic drug, suggesting its use in treating anxiety and related disorders.
Used in Research Chemicals:
Methyl 3-(1-piperazinyl)benzoate is utilized as a research chemical, aiding in the development of new therapeutic agents and expanding our understanding of its pharmacological profile.

InChI:InChI=1/C12H16N2O2/c1-16-12(15)10-3-2-4-11(9-10)14-7-5-13-6-8-14/h2-4,9,13H,5-8H2,1H3

Upstream product

• 179003-10-2 tert-butyl 4-(3-(methoxycarbonyl)phenyl)-piperazine-1-carboxylate 
• 618-89-3 methyl 3-bromobenzoate 
• 67-56-1 methanol 
• 446831-28-3 3-(piperazin-1-yl)benzoic acid 
• 4518-10-9 Methyl 3-aminobenzoate 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 179003-10-2 tert-butyl 4-(3-(methoxycarbonyl)phenyl)-piperazine-1-carboxylate 
• 1447331-70-5 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid methyl ester 
• 1447331-52-3 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid methyl ester 
• 193818-13-2 4-(3-carboxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 1447330-50-8 3-[1-oxo-6-(3-piperazinium-4-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]butyric acid chloride 
• 1447330-37-1 3-[1-oxo-6-(3-piperazinium-1-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]propionic acid trifluoroacetate 
• 1447332-14-0 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid 
• 1447332-02-6 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid 

Relevant academic research and scientific papers

Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th

Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive disease resulting from the deposition of toxic fibrils in tiss

LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME

LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selecte

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

Structure-activity relationship of sulfonyl piperazine LpxH inhibitors analyzed by an LpxE-coupled malachite green assay

The UDP-2,3-diacylglucosamine pyrophosphatase LpxH in the Raetz pathway of lipid A biosynthesis is an essential enzyme in the vast majority of Gram-negative pathogens and an excellent novel antibiotic target. The 32P-radioautographic thin-layer chromatography assay has been widely used for analysis of LpxH activity, but it is inconvenient for evaluation of a large number of LpxH inhibitors over an extended time period. Here, we report a coupled, nonradioactive LpxH assay that utilizes the recently discovered Aquifex aeolicus lipid A 1-phosphatase LpxE for quantitative removal of the 1-phosphate from lipid X, the product of the LpxH catalysis; the released inorganic phosphate is subsequently quantified by the colorimetric malachite green assay, allowing the monitoring of the LpxH catalysis. Using such a coupled enzymatic assay, we report the biochemical characterization of a series of sulfonyl piperazine LpxH inhibitors. Our analysis establishes a preliminary structure-activity relationship for this class of compounds and reveals a pharmacophore of two aromatic rings, two hydrophobic groups, and one hydrogen-bond acceptor. We expect that our findings will facilitate the development of more effective LpxH inhibitors as potential antibacterial agents.

TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αiIbβ3

A series of novel RGD mimetics containing phthalimidine fragment was designed and synthesized. Their antiaggregative activity determined by Born's method was shown to be due to inhibition of fibrinogen binding to αIIbβ3. Molecular docking of RGD mimetics to αIIbβ3 receptor showed the key interactions in this complex, and also some correlations have been observed between values of biological activity and docking scores. The single crystal X-ray data were obtained for five mimetics.

Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture

The RNA replication machinery of HCV is a multi-subunit membrane-associated complex. NS5A has emerged as an active component of HCV replicase, possibly involved in regulation of viral replication and resistance to the antiviral effect of interferon. We report here substituted piperazinyl-N-(aryl)benzamides as potent inhibitors of HCV replication exerted via modulation of the dimerization of NS5A.